Functional Outcomes After Management of End-stage Neurological Bladder Dysfunction With Ileal Conduit in a Multiple Sclerosis Population: A Monocentric Experience

2012 ◽  
Vol 2012 ◽  
pp. 162
Author(s):  
E.S. Rovner
Urology ◽  
2011 ◽  
Vol 78 (4) ◽  
pp. 937-941 ◽  
Author(s):  
Guillaume Legrand ◽  
Morgan Rouprêt ◽  
Eva Comperat ◽  
Alexia Even-Schneider ◽  
Pierre Denys ◽  
...  

2013 ◽  
Vol 3 (1) ◽  
Author(s):  
Hiromitsu Negoro ◽  
Sarah E. Lutz ◽  
Louis S. Liou ◽  
Akihiro Kanematsu ◽  
Osamu Ogawa ◽  
...  

2001 ◽  
Vol 33 (6) ◽  
pp. 2984-2985 ◽  
Author(s):  
W.C Nahas ◽  
E Mazzucchi ◽  
I Antonopoulos ◽  
F.T.E Denes ◽  
E David-Neto ◽  
...  

2021 ◽  
Author(s):  
Nikos Evangelou ◽  
Afagh Garjani ◽  
Sameer Patel ◽  
Dhiren Bharkhada ◽  
Waqar Rashid ◽  
...  

Abstract This study aimed to understand changes in the risk of SARS-CoV-2 infection among all people with multiple sclerosis (MS) receiving immunomodulatory disease-modifying therapies (DMTs) in England, compared to the general population, following mass vaccination. Longitudinal data collected by the National Health Service (NHS) England on all MS DMT prescriptions and the UK Health Security Agency on all registered SARS-CoV-2 test results were analysed. The incidence rate ratio of SARS-CoV-2 infection among people with MS taking DMTs compared to the general population was calculated before (November 2020-January 2021) and after (July-August 2021) mass vaccination. Risk of SARS-CoV-2 infection among people on ocrelizumab or fingolimod compared to the general population increased following liberalisation of COVID-19 restrictions (during March-July 2021) despite mass vaccination. No changes were found with other DMTs. These findings converge with the impaired immune response to vaccines observed with ocrelizumab and fingolimod.


2020 ◽  
pp. 193864002095089
Author(s):  
Michael J. Symes ◽  
Alastair Younger ◽  
Mario Escudero ◽  
Murray J. Penner ◽  
Kevin Wing ◽  
...  

In end-stage ankle arthritis, little is known about the impact of concomitant knee pathology, including the impact of ipsilateral knee pain on total ankle arthroplasty (TAA) outcomes. The aim of this study was to determine the prevalence of ipsilateral preoperative knee pain in patients undergoing TAA and analyze its impact on patient-reported functional outcome measures (PROMs). A retrospective review was performed on the Vancouver End Stage Ankle Arthritis Database at a single institution. In total, 114 patients were studied, with patient demographics collected preoperatively, including the presence or absence of knee pain. Postoperative follow-up was performed at 5 years, primarily analyzing disease-specific PROMs, including the Ankle Osteoarthritis Score (AOS) and Ankle Arthritis Score (AAS). Multivariate mixed-effects linear regression models compared the scores between the groups. In total, 31 patients (27.2%) presented with concomitant ipsilateral knee pain. Despite more females in the knee pain group (64.5% vs 36.1%) there were no other significant differences at baseline between the knee pain and no knee pain groups in terms of demographics or baseline primary disease specific PROMs. At 5 years, the patients with knee pain had significantly worse AAS (37.9 ± 23.8 vs 21.2 ± 16.3, P = .004) and AOS total scores (38.1 ± 24.1 vs 21.9 ± 15.5, P = .005) compared with the no-knee pain group. Both groups improved significantly from baseline across all outcome measures; however, the magnitude of improvement was less in the knee pain group. Our study demonstrated that over one-quarter of patients with end-stage ankle arthritis undergoing TAA present with ipsilateral concomitant knee pain. If present, it is associated with worse functional outcomes at the 5-year mark. Further studies are needed to evaluate if knee pain influences complications, implant failure rates, and survival. Levels of Evidence: Level III


2019 ◽  
Vol 26 (8) ◽  
pp. 902-911 ◽  
Author(s):  
Julie Yoon Moberg ◽  
Bjarne Laursen ◽  
Lau Caspar Thygesen ◽  
Melinda Magyari

Background: A diagnosis of multiple sclerosis (MS) may impact the choice of parenthood. Objective: To investigate the number of live births, abortions and ectopic pregnancies among persons with MS. Methods: From the Danish Multiple Sclerosis Registry, we extracted data from all persons diagnosed with MS from 1960 to 1996 and matched each MS person with four reference persons. We used a negative binomial regression model for the live births and Poisson regression model for abortions and ectopic pregnancies. The total fertility rate (TFR) during 1960–2016 and the annual number of live births in the MS population were analysed. Results: Persons with MS had fewer children than reference persons. Fewer women with MS had elective abortions after diagnosis (incidence rate ratio (IRR) = 0.88; 95% confidence interval (CI) = 0.78–1.00) than reference persons. There was no difference regarding the number of elective abortions, spontaneous abortions or ectopic pregnancies after onset. The TFR was lower for women with MS than for reference persons, and the number of annual live births by MS persons increased during 1960–2016. Conclusion: MS seems to considerably impact reproductive choices, especially after clinical diagnosis, resulting in the MS population having fewer children than the general population.


Sign in / Sign up

Export Citation Format

Share Document